Article
The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non-small cell lung cancer: A meta-analysis.
The clinical respiratory journal - 1 Apr 2024
Guo Liuxian, Zhou Guojin, Huang Min, Tang Kejing, Xu Jing, Chen Jie
Abstract excerpt
BACKGROUND: Previous studies have suggested that loss of the EGFR T790M gene mutation may contribute to the development of resistance to Osimertinib in non-small cell lung cancer (NSCLC). AIMS: This study aims to assess the relationship between the clinical effectiveness of Osimertinib in NSCLC patients and the T790M mutation status following resistance to Osimertinib and examine differences between plasma and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.